Zanvastro and Etcamah lead the Aug. 29–Sep. 4 FDA approval ledger
A date-bounded review of Zanvastro, Etcamah, generic and supplemental FDA drug actions, and the current gap in the public device ledger, with clinical and commercial context.
The FDA's seven-day approval window from August 29 through September 4, 2026 produced two clinically substantive new-drug actions: Ionis Pharmaceuticals' Zanvastro for Alexander disease and AstraZeneca's Etcamah for a biomarker-defined breast-cancer population. The captured Drugs@FDA report also lists a generic difelikefalin approval and a set of labeling, chemistry, manufacturing and controls (CMC), Risk Evaluation and Mitigation Strategies (REMS), and tentative actions. 1
The device portion remains a captured official ledger rather than a complete seven-day census. The FDA's downloadable 510(k) file and PMA decision feed exposed records through August 28 in this run, with no item-level records for August 29–September 4. That lag does not establish that the agency issued no device decisions after August 28. 23
At a glance
| Action | FDA date | Population or use | Sponsor/applicant | Regulatory and commercial read |
|---|---|---|---|---|
| Zanvastro (zilganersen) | Sep. 3 | Pediatric and adult patients with Alexander disease | Ionis Pharmaceuticals, Inc. | First FDA-approved treatment for an ultra-rare disease; launch depends on specialist administration, reimbursement, and treatment-center access. |
| Etcamah (camizestrant) plus Guardant360 CDx | Sep. 4 | Adults with ESR1-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer during aromatase-inhibitor and CDK4/6-inhibitor therapy | AstraZeneca; Guardant360 CDx from Guardant Health | Accelerated approval inserts an oral, biomarker-guided switch into an established treatment sequence; confirmatory evidence and mutation testing will shape uptake. |
| Difelikefalin acetate injection | Aug. 31 | Generic equivalent to the reference product Korsuva | Qilu Pharm Hainan | An additional AP-rated IV supply can increase competition; the FDA record supplies no price or market-size signal. |
| Other captured Drugs@FDA actions | Aug. 31–Sep. 2 | Labeling, CMC, REMS, tentative, and other application actions | Multiple applicants | These records indicate regulatory throughput. The available report does not provide enough detail to call most of them new clinical indications or commercial launches. |
| Medical devices | Captured through Aug. 28 | 510(k) and PMA records | — | Current-week item-level coverage remains pending on the public FDA surfaces reviewed. |
The table consolidates duplicate dosage-form or presentation rows where the report repeated the same application and submission. A routine database action appears below only in the action class supplied by Drugs@FDA.
Drug and biologic approvals
Zanvastro: a first approved treatment for Alexander disease
The FDA approved Zanvastro (zilganersen), Ionis Pharmaceuticals' antisense oligonucleotide, on September 3 for pediatric and adult patients with Alexander disease. Alexander disease is a rare neurological disorder caused by abnormal glial fibrillary acidic protein, or GFAP, production; the FDA says the disease affects fewer than one in a million people. Zanvastro is administered as a 50 mg intrathecal injection by a trained health professional once every three months. 45
The approval covers a wide age range because the FDA evaluated evidence from infancy through adulthood. The agency cited a multicenter randomized controlled study of 49 patients aged two years and older and an open-label substudy of four patients younger than two. The common adverse effects included vomiting, back pain, cough, headache, and post-lumbar-puncture syndrome. Aseptic meningitis is a safety concern. 4
Ionis reported that the pivotal study showed stabilization of gait speed. In the 50 mg cohort, the least-squares mean difference was 33.3% at week 61, with a p-value of 0.041. Ionis said U.S. availability was expected in the coming weeks and that it would provide patient support and insurance-assistance programs. Recordati holds exclusive rights outside the United States, with European and Japanese submissions expected in 2027. Those launch and geographic statements come from Ionis and should be treated as company guidance. 6
Commercial read
Zanvastro combines a first approved disease-modifying treatment with a very small addressable population. Reuters reported Ionis' price at $285,000 per dose, with dosing every quarter, and reported that the company expects peak sales above $100 million. Reuters also cited an estimate of fewer than 1,000 U.S. patients from the National Institutes of Health. The price, patient count, and sales forecast are attributed estimates rather than FDA market data. 7
The commercial question is execution at specialist sites rather than mass-market volume. Patients and advocates will need to watch treatment-center availability, payer decisions, and the practical burden of quarterly lumbar administration. Clinicians will need to balance the gait result and the broad age range against the administration and meningitis risks in the label. Investors will need launch evidence before treating the approval as a large-revenue event.
Approval-linked analyst commentary was available. Reuters reported Oppenheimer analyst Jay Olson's view that the approval meaningfully de-risked Ionis' broader neurology pipeline. H.C. Wainwright separately reiterated a Buy rating and a $115 price target, and its report raised the modeled probability of approval from 75% to 100% while moving the valuation model from about $22.4 billion to $22.5 billion. Those are analyst opinions and model changes. A comparable approval-day Ionis share-price reaction was not independently verified from a clean event-specific price series in this run. 78
Etcamah: an ESR1-guided switch before progression
The FDA granted accelerated approval to Etcamah (camizestrant) on September 4 for adults with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer when an ESR1 mutation is detected during aromatase-inhibitor and CDK4/6-inhibitor therapy. The label requires an FDA-authorized test to identify the mutation. Etcamah is taken orally at 75 mg once daily with a CDK4/6 inhibitor. 9
The same FDA action approved Guardant360 CDx as a companion diagnostic for identifying eligible patients. The approval page describes the test's role, while the current CDRH export reviewed for this issue did not expose a matching item-level 510(k) or PMA record number. The record therefore supports the companion-diagnostic authorization without supplying a device application number for this article. 9
The approval rests on SERENA-6, a randomized, double-blind, placebo-controlled trial of 315 patients. Median progression-free survival was 16.0 months with camizestrant and 9.2 months with the control regimen. The hazard ratio was 0.44, with a 95% confidence interval of 0.31 to 0.60 and p < 0.00001. Overall-survival data were immature at the time of the FDA action. 9
The label carries a boxed warning for QTc-prolongation arrhythmia risk when Etcamah is used with QTc-prolonging drugs. The label also warns about bradycardia and embryo-fetal toxicity. Continued approval depends on confirmatory clinical-benefit verification because the FDA used the accelerated-approval pathway. 9
Commercial read
Etcamah enters a large established treatment setting, but the approved population is defined by both disease biology and treatment timing. The control arm in SERENA-6 reflects the existing aromatase-inhibitor plus CDK4/6-inhibitor sequence; the new product is positioned for patients whose tumors acquire an ESR1 mutation while that sequence is underway. The commercial gate is therefore routine mutation testing, a fast switch in therapy, and durable evidence that the progression-free-survival gain translates into confirmed clinical benefit.
The FDA action does not supply a market-size or price estimate, so this issue assigns neither. No approval-specific AstraZeneca share reaction, analyst-rating change, or institutional commentary was independently verified for this issue. Clinicians should focus on test access, drug-interaction management, QTc monitoring, and the accelerated-approval status. Patients and advocates should track whether mutation testing and the required switch are available through the care pathway.
Other captured Drugs@FDA actions
Drugs@FDA's recent-approvals report covers two weeks and includes final and tentative approvals of original and supplemental applications. The report warns that some approvals may enter the database after the listed period and points readers to the monthly All Approvals report for a more comprehensive view. The entries below are limited to records dated August 31 through September 2 in the captured report. 1
Generic approval with a clear product link
On August 31, Drugs@FDA listed an approved ANDA for intravenous difelikefalin acetate, application 220919, from Qilu Pharm Hainan. The FDA application record classifies the product as an AP therapeutic-equivalence entry and identifies Korsuva, NDA 214916, as the reference product. This is a generic entry, rather than a new molecular entity or a novel NDA/BLA approval. 1011
Commercial read: An additional AP-rated IV supply can increase competition around Korsuva. The FDA records reviewed here provide no price, launch timing, or market-size evidence, so the commercial effect remains a supply-side possibility rather than a measured sales change.
Grouped routine and tentative actions
| FDA date | Action class shown in the report | Captured applications or products |
|---|---|---|
| Sep. 2 | Approved ANDA entries | Alendronate sodium, ANDA 214523, Precision Dose Inc.; sacubitril/valsartan, ANDA 213631. |
| Sep. 2 | Labeling supplements | Avtozma, BLA 761420 and 761498; bupropion hydrochloride, ANDA 079095; Cibinqo, NDA 213871; divalproex sodium, ANDA 090062; Etopophos Preservative Free, NDA 020457; Fyarro, NDA 213312; oxcarbazepine, ANDA 078734; and other entries listed by the report. |
| Sep. 2 | CMC, REMS, and tentative actions | Dapagliflozin, ANDA 211482, CMC; pimavanserin, ANDA 214750, tentative; relugolix, ANDA 219913, tentative; thalidomide, ANDA 213267, REMS; Thalomid, NDA 020785, REMS. |
| Sep. 1 | Labeling supplements | Byooviz, BLA 761202; Cleocin Hydrochloride, NDA 050162; Krazati, NDA 216340; nelarabine, ANDA 216038; and other entries listed by the report. |
| Sep. 1 | Tentative action | Sheur, ANDA 217650. |
| Aug. 31 | Approved ANDA entries | Difelikefalin acetate, ANDA 220919; pomalidomide applications 210232, 213234, 219718, and 220741; sodium sulfate/potassium sulfate/magnesium sulfate, ANDA 219429. |
| Aug. 31 | Labeling and CMC actions | Bavencio, BLA 761049; Imfinzi, BLA 761069; Libtayo, BLA 761097; Loqtorzi, BLA 761240; Penpulimab-kcqx, BLA 761258; Unloxcyt, BLA 761297; and other entries listed by the report. |
The report supplies action classes for these rows without item-level descriptions of a new indication for most supplements. The table therefore records the regulatory event and leaves clinical-change claims open until the relevant label, approval letter, or product history supplies them.
Medical devices
The FDA's current downloadable 510(k) file contained decisions dated July 1 through August 28 when captured for this issue, and the PMA RSS feed exposed decisions through August 28. The PMA overview page was also updated August 24. The public surfaces reviewed here did not expose item-level 510(k) or PMA decisions dated August 29 through September 4. 2312
This issue therefore reports the official device surfaces captured through August 28 and flags the current-week gap. The gap matters for investors tracking device-company catalysts and for clinicians or advocates waiting for intended-use details. A delayed public file can add records later, so the absence of an item in this capture should not be read as a finding that no 510(k) clearances or PMA decisions occurred during the seven-day window.
Etcamah's FDA page separately identifies Guardant360 CDx as the companion diagnostic for the drug approval. That statement belongs to the drug action above; the current device export did not provide an item-level record number that would support treating it as a separately listed current-week 510(k) or PMA event. 9
What matters next
- Zanvastro: Watch for U.S. treatment-center activation, payer coverage, and early launch data. Those measures will test whether a quarterly intrathecal therapy can reach the very small population implied by the disease's rarity and Ionis' stated sales target.
- Etcamah: Track ESR1 testing volume and time-to-switch in clinical practice. The approval's value depends on finding eligible patients during the specified treatment sequence, while confirmatory evidence will determine whether the accelerated approval converts into a durable product position.
- Difelikefalin: Watch for launch and pricing evidence from Qilu Pharm Hainan or competing suppliers. The FDA approval establishes an additional approved product; it does not establish a price cut or a change in Korsuva sales.
- Routine FDA actions: Read the underlying labels and approval letters before treating a labeling row as an efficacy expansion, a new population, or a market-moving event.
- Devices: Recheck the FDA 510(k) download, PMA feed, and individual decision pages next week. The current capture ends August 28, so the seven-day device ledger remains open.
References
- 1Recent New and Generic Drug Approvals
accessdata.fda.gov
- 2
- 3FDA PMA decision RSS feed
accessdata.fda.gov
- 4
- 5Zanvastro FDA application record, NDA 220210
accessdata.fda.gov
- 6Zanvastro approved by FDA for Alexander disease
ir.ionis.com
- 7
- 8
- 9
- 10Difelikefalin acetate FDA application record, ANDA 220919
accessdata.fda.gov
- 11Korsuva FDA application record, NDA 214916
accessdata.fda.gov
- 12FDA PMA database
accessdata.fda.gov
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.